Pacific Biosciences of California, Inc.
Here’s whether Pacific Biosciences of California, Inc. (PACB) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.37% over 10 days); strong 1-year return of +45.0%. Concerns: trading below the 200-day MA (long-term downtrend); RSI 72 — overbought, elevated pullback risk. Currently 46.9% off its 52-week high. Score: +0/7.
PACB is trading below its 200-day MA ($1.68) — a key warning sign the longer-term trend is under pressure. With an RSI of 72.0, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +45.0% compares to +24.4% for SPY (beat the market by 20.6%). The current 46.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.